These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Advances in the management of thyroid eye diseases: An overview. Kumari R; Chandra Saha B Int Ophthalmol; 2018 Oct; 38(5):2247-2255. PubMed ID: 28822031 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Salvi M; Vannucchi G; Campi I; Rossi S; Bonara P; Sbrozzi F; Guastella C; Avignone S; Pirola G; Ratiglia R; Beck-Peccoz P Eur J Endocrinol; 2006 Apr; 154(4):511-7. PubMed ID: 16556712 [TBL] [Abstract][Full Text] [Related]
10. A New Era in the Treatment of Thyroid Eye Disease. Patel A; Yang H; Douglas RS Am J Ophthalmol; 2019 Dec; 208():281-288. PubMed ID: 31377284 [TBL] [Abstract][Full Text] [Related]
11. [Biological treatment options for Graves' ophthalmopathy]. El Fassi D; Nielsen CH; Hegedüs L Ugeskr Laeger; 2008 Jun; 170(24):2128-30. PubMed ID: 18565294 [TBL] [Abstract][Full Text] [Related]
12. Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy. Janssen JAMJL; Smith TJ Cells; 2021 Feb; 10(2):. PubMed ID: 33673340 [TBL] [Abstract][Full Text] [Related]
13. Update on Graves disease: advances in treatment of mild, moderate and severe thyroid eye disease. Strianese D Curr Opin Ophthalmol; 2017 Sep; 28(5):505-513. PubMed ID: 28700384 [TBL] [Abstract][Full Text] [Related]
14. Medical Therapy in Patients with Moderate to Severe, Steroid-Resistant, Thyroid Eye Disease. Toro-Tobon D; Rachmasari KN; Bradley EA; Wagner LH; Tooley AA; Stokken JK; Stan MN Thyroid; 2023 Oct; 33(10):1237-1244. PubMed ID: 37515425 [No Abstract] [Full Text] [Related]
15. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies. Winn BJ; Kersten RC Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408 [TBL] [Abstract][Full Text] [Related]
16. Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach. Sipkova Z; Insull EA; David J; Turner HE; Keren S; Norris JH Clin Endocrinol (Oxf); 2018 Dec; 89(6):834-839. PubMed ID: 30103255 [TBL] [Abstract][Full Text] [Related]
17. [Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?]. Wall JR; Lahooti H Endokrynol Pol; 2011; 62 Suppl 1():1-7. PubMed ID: 22125104 [TBL] [Abstract][Full Text] [Related]
18. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives. Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373 [TBL] [Abstract][Full Text] [Related]